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doi:10.1016/j.kjms.2011.10.019Abstract Acute lung injury is an inflammatory syndrome that increases the permeability of
the blood-gas barrier, resulting in high morbidity and mortality. Despite intensive research,
treatment options remain limited. We investigated the protective efficacy of tezosentan,
a novel, dual endothelin receptor antagonist, in an experimental model of alpha-
naphthylthiourea (ANTU)-induced acute lung injury in rats. ANTU was intraperitoneally (i.p.)
injected into rats at a dose of 10 mg/kg. Tezosentan was injected 30 minutes before ANTU
was subcutaneously (s.c.) injected at doses of 2, 10, or 30 mg/kg, 60 minutes before ANTU
was injected at doses of 2, 10, or 30 mg/kg (i.p.), and 90 minutes before ANTU at a dose of
10 mg/kg (i.p.). Four hours later, the lung weight/body weight (LW/BW) ratio and pleural effu-
sion (PE) were measured. When injected 30 minutes before ANTU at doses of 2, 10, or 30 mg/kg
(s.c.), tezosentan had no effect on lung pathology. When injected 60 minutes before ANTU at
doses of 2, 10, or 30 mg/kg (i.p.) or 90 minutes before ANTU (10 mg/kg, i.p.), tezosentan
significantly decreased the PE/BW ratio and had a prophylactic effect on PE formation at all
doses. Therefore, tezosentan may attenuate lung injury. Furthermore, its acute and inhibitory
effects on fluid accumulation were more effective in the pleural cavity than in the interstitial
compartment in this experimental model.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Karaelmas Universitesi, Tip
0 KozlueZonguldak, Turkey.
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vier Taiwan LLC. All rights reservIntroduction
Acute lung injury (ALI) and its more severe form, acute
respiratory distress syndrome (ARDS), are syndromes of
acute respiratory failure that are secondary to increased
permeability and noncardiogenic pulmonary edema [1e4].
ALI/ARDS is a major cause of morbidity, death, and cost ined.
Table 1 Descriptions of the study groups.
Groups Chemicals Route
1 Control N/A
2 Olive oil i.p.
3 ANTU (10 mg/kg) i.p.
4 ANTU þ Tezosentan (2 mg/kg)a i.p./s.c.
5 ANTU þ Tezosentan (10 mg/kg)a i.p./s.c.
6 ANTU þ Tezosentan (30 mg/kg)a i.p./s.c.
7 ANTU þ Tezosentan (2 mg/kg)b i.p./i.p.
8 ANTU þ Tezosentan (10 mg/kg)b i.p./i.p.
9 ANTU þ Tezosentan (30 mg/kg)b i.p./i.p.
10 ANTU þ Tezosentan (10 mg/kg)c i.p./i.p.
a Tezosentan was administered 30 minutes before ANTU
injection.
b Tezosentan was administered 60 minutes before ANTU
injection.
c Tezosentan was administered 90 minutes before ANTU
injection.
Tezosentan and acute lung injury 73intensive care units. The American-European consensus
conference on ARDS defined ALI/ARDS as a “syndrome of
inflammation and increased permeability.” Hence, it is now
widely accepted that the pathophysiology of ALI/ARDS is
driven by aggressive inflammatory reactions that damage
the alveolar-capillary units [3e5]. Inflammatory mediators
directly amplify endothelial injuries or recruit inflamma-
tory cells into the vascular, interstitial, and alveolar spaces
[5,6]. However, the mechanisms that result in lung injury,
the time course of these syndromes, the involved inflam-
matory pathways, and associated cell repair processes are
not well understood [7].
The endothelins (ETs) are a family of 21 amino acid
peptides with powerful vasoconstrictive properties [8]. At
least three isoforms of ET have been identifieddET-1, ET-2,
and ET-3. ET-1 is the most common. Two main ET receptors
have also been identified: ETA and ETB [9]. Initially
described as strong vasoconstrictors, ETs are now also
believed to have potent proinflammatory effects [2]. For
example, transgenic mice that overexpress ET-1 release
increased amounts of tumor necrosis factor (TNF)-a,
interferon-g, interleukin (IL)-1, and IL-6 [10]. ETs are
abundant in the lungs and are synthesized in both the
airways and pulmonary vasculature. Because ET-1 may act
as an immune modulator, an increase in ET-1 may
contribute to lung injuries by inducing the expression of
cytokines, including TNF, IL-6, and IL-8 [9]. All these find-
ings suggest that ET-1 has a role in respiratory physiology
and pathophysiology. The ET system is activated in clinical
settings and, following various types of experimental lung
injuries, ET receptor antagonists have been reported to
affect different levels of pathophysiology [10e13].
Alpha-naphthylthiourea (ANTU), a widely used rodenti-
cide, causes ALI in a dose-dependent manner by changing
the permeability of the lung microvasculature [14].
Because the effects of ANTU are specifically directed at the
lungs, the use of this agent has become a popular means of
investigating the physiological changes that result from
acute lung injury [15e17]. Morphological studies indicate
that the capillary endothelial cells of the lung are the
primary cellular target of ANTU toxicity. Injury to the
endothelium appears as blebbing and scalloping of the cell
surface, eventually resulting in the loss of the endothelial
barrier. This loss of endothelial barrier integrity results in
increased capillary permeability and the production of
interstitial and alveolar edema [18,19]. There are no
reports on the effects of tezosentan on ANTU-induced ALI.
Therefore, this study investigated the effect of the novel,
dual ET receptor antagonist, tezosentan, on an ANTU-
induced model of ALI in rats.
Materials and methods
Animal model/assessment of ALI
This study was carried out using Wistar albino male rats
weighing 200e240 g (animal laboratory of Zonguldak
Karaelmas University, Zonguldak, Turkey). The rats were
housed under standard laboratory conditions with a 12-h
light/dark cycle and were allowed free access to food and
water. The procedures and protocols of this study were inaccordance with our institutional guidelines, which parallel
the Guide for the Care and Use of Laboratory Animals (U.S.
National Institutes of Health, 1985). Approval for this study
was obtained from the Animal Experiments Local Ethics
Committee of Zonguldak Karaelmas University.
During the experiment, the animals were placed in
separate cages and kept at room temperature (22 C). ANTU
(suspended in olive oil at a concentration of 4 mg/mL) was
injected intraperitoneally (i.p.) at a dose of 10 mg/kg.
When injected into the rats, ANTU produces pulmonary
edema, as indicated by increases in the lung weight/body
weight ratio (LW/BW) and pleural effusion (PE), reaching
its maximum effect within 4 hours. The control group
received the same volume of just olive oil. Four hours later,
the animals were anesthetized with thiopental sodium
(50 mg/kg i.p.) and exsanguinated by cutting the abdominal
aorta.
The thorax was then opened, and any PE was carefully
collected by suction and the volume was measured. Care
was also taken to prevent contamination of the PE with
blood. The lungs were removed, and all surrounding tissues
were dissected and weighed using an analytical balance.
The volume of the PE (mL) and the LW/BW and pleural
effusion/body weight (PE/BW) ratios were calculated and
as indices of ALI.
Experimental protocol
The animals were divided into 10 groups of 10 animals per
group. The groups are described in Table 1. Tezosentan was
dissolved into a solution of sterile saline. All of the drugs
were prepared daily. The drug solution was kept in dark
containers in order to protect it from light-induced
decomposition.
Histological examination
For the histopathological examinations, the lungs were
immersed in 10% formalin and allowed to fix for 2e3 days.
Then, 10-mm cross sections were processed for standard
Figure 1. (A) Normal histological appearance of olive oil-
injected lungs. Representative hematoxylin-eosin (H-E) stain-
ing (40 magnification). (B) Prominent perivascular, peri-
bronchial, and alveolar septal edema, erythrocyte
extravasation, and inflammatory cell infiltration after ANTU
treatment (H-E, 10). (C) Higher magnification of pathology
due to ANTU (H-E, 40).
74 F. Atalay et al.hematoxylin and eosin (H-E) staining. All of the lobes of
each lung were subject to histological examination. Then,
the sections were examined by light microscopy and
photographed.
Chemicals
The following chemicals were used in this study: a-
naphthylthiourea (Interchim, Montluc¸on, France) was
suspended in olive oil (4 mg/ml) and was a gift from
Dr. E. Schillinger, Schering AG, Berlin, Germany. Olive oil
was purchased from Sigma (St. Louis, MO, USA). Tezosentan
was purchased from Actelion Pharmaceuticals LTD, 4123
Allschwil, Switzerland.
Statistical analysis of results
The results are expressed as means  SEM. The groups were
compared using one-way analysis of variance (ANOVA),
followed by the Tukey test when significance was indicated.
A p-value of <0.05 was considered significant. Statistical
analyses were performed using SPSS for Windows 13.0 (SPSS
Inc., Chicago, IL, USA).
Results
Effects of a-naphthylthiourea on the pulmonary
vasculature
Upon histopathological examination, ANTU triggered severe
pulmonary injury, as indicated by perivascular, peribron-
chial, and alveolar septal edema, erythrocyte extravasa-
tion, and inflammatory cell infiltration (Fig. 1B, C); no
changes were observed in the control or olive oil-treated
rats (Fig. 1A). Therefore, the olive oil group was used as
a control group.
Significant lung edema developed 4 hours after the i.p.
injection of 10 mg/kg ANTU, as indicated by an increase in
the LW/BW ratio and PE when compared with the control
rats. The LW/BW ratio was 67.8  3.2  104 for ANTU-
treated rats and 44.4  1.8  104 for the control rats
(p < 0.05) (Fig. 2A). A mean volume of 4.1  0.4 mL PE was
extracted from the ANTU-treated rats; none was extracted
from the control rats (p < 0.05) (Fig. 2B, C).
The effects of tezosentan on ANTU-induced
pulmonary edema
When injected 30 minutes before ANTU at doses of 2, 10, or
30 mg/kg s.c., tezosentan produced no prophylactic effects
on ANTU-induced pulmonary edema (LW/BW ratio) (Fig. 2A)
or PE formation (Fig. 2B, C).
When injected 60 min before ANTU at doses of 2, 10, or
30 mg/kg i.p., tezosentan led to a significant drop in the
PE/BW ratio (p < 0.05) and had a prophylactic effect on
ANTU-induced PE formation at every dose tested (Fig. 2B,
C). Although the 30-mg/kg dose of tezosentan did not
significantly affect the LW/BW ratio, it did cause a reduc-
tion in lung injury, as shown by the results of the histo-
pathological examination of this group (Fig. 3).When injected 90 min before ANTU at a dose of 10 mg/kg
i.p., tezosentan caused a significant decrease in PE
formation (p < 0.05) (Fig. 2B, C). The most significant
protective effect on PE formation was seen in this group.
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Figure 2. ANTU-induced lung injury and changes that
resulted from tezosentan, as evaluated by the changes in the
lung weight/body weight (LW/BW) ratio (104) (A), volume of
pleural effusion (PE) (mL) (B), and pleural effusion/body
weight (PE/BW) ratio (104) (C). Each column shows the mean
value of 10 experiments. Vertical bars on the columns repre-
sent the SEM. * p < 0.05.
Figure 3. Histopathological examination showing a reduc-
tion in lung injury after pretreatment with tezosentan (30 mg/
kg, i.p.) 60 minutes before ANTU (H-E, 10).
Tezosentan and acute lung injury 75Tezosentan significantly increased the LW/BW ratio of this
group (Fig. 2A).
Discussion
This study is the first to show that tezosentan, a dual
endothelin ETA/ETB receptor antagonist, causes significant
inhibition of PE (PE/BW ratio) formation when injected i.p.
60 and 90 min before ANTU administration and has
a prophylactic effect on ANTU-induced PE formation.
Conversely, it had no significant preventive effect on
pulmonary edema (LW/BW ratio). The preventive effect of
tezosentan on PE was seen only following i.p. injection.Furthermore, tezosentan caused an increase in the LW/BW
ratio when injected (i.p.) 90 min before ANTU. Therefore,
tezosentan has complex effects on the pathology of this
ANTI-induced ALI model that depend on the dose, appli-
cation time, and route, similar to that noted in the litera-
ture [12].
When injected i.p., tezosentan significantly decreased
the PE/BW ratio and had a prophylactic effect on ANTU-
induced PE formation at all doses. When injected s.c. at the
same doses, it had no prophylactic effect on ANTU-induced
PE formation. These results suggest that the i.p. adminis-
tration of tezosentan was more effective in our experi-
ment. Whether administered via i.p. or s.c. injection,
tezosentan had no prophylactic effect on ANTU-induced
changes to the LW/BW ratio.
Our results show that a single i.p. injection of tezo-
sentan significantly decreases PE formation. Plasma
leakage into the pleural cavity and fluid accumulation in
the interstitial compartment are important pathophysio-
logical changes in ANTU-induced ALI. Many edemagenic
agents have been reported to cause pulmonary endothelial
damage, which allows excessive fluid to invade into
the interstitium. There are three possible routes for the
subsequent escape of excessive fluid: clearance by the
lymphatic system, passage into the alveolar airways, and
passage into the pleural cavity. The majority of edemagenic
agents enhance the passage of fluid into the alveolar
airways, presumably by damaging the alveolar epithelium
lining, resulting in alveolar edema. However, ANTU causes
severe PE, possibly because of the sensitivity of the
mesothelial cell lining layer and because it targets capillary
endothelial cells [14]. The exact mechanism responsible for
the formation of PE is unclear, but we postulate that the
acute inhibitory effects of tezosentan on fluid accumula-
tion have a greater effect on the pleural cavity than the
interstitial compartment in this model of ALI. The mecha-
nisms responsible for the effects of tezosentan on PE
pathophysiology are an important and poorly understood
subject. However, we have insufficient data that can be
used to reach a conclusion about the augmentative effects
76 F. Atalay et al.of tezosentan on pulmonary edema (LW/BW ratio) at a dose
of 10 mg/kg when injected 90 minutes before ANTU. This is
still under investigation in our laboratories.
Alpha-naphthylthiourea produces relatively selective
pulmonary toxicity, as manifested by nonhemorrhagic
edema and extensive PE. The exact mechanisms that are
responsible for ANTU in pulmonary tissues are not clear.
It has been postulated that vasoactive substances that
originate from the pulmonary vasculature and airways
contribute to ANTU-induced pulmonary edema. The mech-
anisms of ANTU-induced lung damage have been studied
extensively and result in prominent damage to the vascular
endothelium. This damage is partially mediated by arach-
idonic acid metabolites [20]. Following the intravenous
(i.v.) injection of radiolabeled ANTU, covalent binding to
macromolecules has been observed in the lungs, and
desulfurization of this toxic compound produces reactive
molecules [21]. ANTU is also partially metabolized by
cytochrome P450 monooxygenase in both the liver and lung
microsomes into an intermediate, which is also capable of
covalent binding [22]. We have shown for the first time the
roles of oxidized low-density lipoprotein [23] and inducible
nitric oxide synthase (iNOS) enzyme [24, 25] in ANTU-
induced ALI.
Additionally, ET-1 has potent constrictor effects on the
arteries in vitro and produces a long-lasting pressor
response. ET-1 mediates the changes seen in pulmonary
hypertension. Endothelin receptor antagonists have been
approved for the treatment of pulmonary arterial hyper-
tension [26]. These drugs may offer new opportunities for
managing patients with lung disease, especially ALI/ARDS,
because no pharmacological agent has been convincingly
shown to improve the clinical prognosis of these patients
[2]. It has been suggested that ETs are involved in the
pathogenesis of ALI [2,8e13,23]. Many types of experi-
mental lung injury result from increased circulating ET-1,
bronchoalveolar lavage (BAL) ET-1, and lung tissue ET-1
[8,27]. The ET-1 levels in humans are also increased in
sepsis, burns, ALI, and ARDS [28,29]. In patients who have
succumbed to ARDS, there was also a marked increase in
tissue ET-1 immunostaining in the vascular endothelium,
alveolar macrophages, smooth muscle, and airway epithe-
lium compared with the lungs of patients who died without
ARDS [30].
The mechanisms by which ET-1 contributes to pulmonary
edema remain uncertain but may include altering the
vascular reactivity, resulting in increased capillary pressure
and fluid filtration [31]; however, the effect of ET-1 on
vascular permeability is controversial. Although several
studies have suggested that ET-1 increases microvascular
permeability [32,33], others have found no effect [34].
However, it has also been suggested that ET-1 decreases
transvascular fluid flux by stabilizing the integrity of the
endothelial barrier [35,36]. Similarly, ET-1 has been shown
to inhibit edema formation that is induced by various
chemical stimuli in rat and rabbit skin [37,38]. In a previous
study [39], we found that i.v. injection of ET-1 into rats 15
minutes before ANTU significantly reduced the LW/BW ratio
at a dose of 3 nmol/kg, but not at doses of 0.3 or 1 nmol/kg.
Furthermore, decreases in the PE/BW ratio were significant
at 1 and 3 nmol/kg ET-1. Phosphoramidon, endothelin
converting enzyme inhibitor, did not alter the edema-producing effect of ANTU indicated the lack of participa-
tion of the ET-peptide cascade in this pathological event.
We suggest that the long-lasting vasoconstrictive nature of
ET-1 may factor into this preventive effect because no
resolution regarding these parameters was observed with
angiotensin II (AT II), a relatively short-acting vasocon-
strictor peptide. Endothelin receptor antagonists have been
evaluated in different animal models of ALI/ARDS. While
studies have shown that they have protective effects in
some models of ALI/ARDS [12,13,40e42], their efficacy may
vary in different experimental models of lung injury or
following different modes of administration. This was
reflected in a study by Hubloue et al. [43] on oleic acid-
induced lung injury in dogs where pretreatment with
bosentan, another dual ET receptor antagonist, reduced
pulmonary hypertension, whereas the same treatment
started 90 minutes after the insult had no effect. Similarly,
Cox et al. [44] found that tezosentan does not provide clear
protection against ALI that was induced by smoke inhala-
tion or burns in sheep. This suggests that the timing of
intervention is important in dynamic progressive processes
such as ALI. Their study supports our results, namely that
tezosentan causes a significant increase in pulmonary
edema formation, unlike the other groups, when injected
i.p. 90 minutes before ANTU. Similarly, Ruetten et al.
[45] found that pretreatment with a nonselective ET
receptor antagonist in endotoxin-challenged rats markedly
augmented hemodynamic deterioration and reduced the
6-hour survival rate. Conversely, Rossi et al. [12] found
that tezosentan efficiently counteracts pulmonary edema
in sepsis-related ALI in pigs at a dose of 1 mg/kg, whereas
a 10-fold greater dose of tezosentan resulted in adverse
effects, most notably hemodynamic deterioration and early
death. These results indicate that tezosentan can have
opposite results depending on the dose and route of
administration.
Our results indicate that ET peptides play a role in ANTU-
induced ALI. Tezosentan has a significant protective effect
on massive PE formation, but it has no preventive effect
on pulmonary edema and no significant histopathological
recovery was observed. These results suggest that the
nonselective ET receptor antagonist, tezosentan, when
administered i.p., has complex effects on inflammation and
tissue injury, as indicated in this and other models of ALI.
Our results corroborate earlier findings regarding the
complex effects of tezosentan on ALI pathology. We
conclude that the ET system is involved in the pathophysi-
ology of lung disease, including ALI, but further studies are
warranted to determine the specific mechanisms respon-
sible for the favorable effects of ET receptors and ET
receptor antagonism.
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